#ScientificSessions26 Late-Breaking Science announced
Six sessions during the meeting are devoted to the presentation of the latest research results.
LBS.01: The Dr. Eugene Braunwald Late-Breaking Science Session: Translating Science Into Prevention: Lessons From Landmark Trials
8:30-9:45 a.m. | Saturday, Nov. 7
· Primary Report of the Ziltivekimab Cardiovascular Outcomes Trial (ZEUS)
· Effect of Pelacarsen on Cardiovascular Outcomes in Patients With Elevated Lipoprotein(a): Primary Results From the Lp(a) HORIZON Trial
· Extended Analyses of Cardiovascular Outcomes With Pelacarsen Treatment in the Lp(a) Horizon Trial
LBS.02: Treating the Clot or Controlling the Blood Pressure: Improving Outcomes After Stroke
1:45-2:45 p.m. | Saturday, Nov. 7
· Intravenous Tirofiban vs. Thrombolysis Before Endovascular Thrombectomy in Acute Ischemic Stroke: The Adjuvant Randomized Clinical Trial (ADJUVANT)*
· Outcomes in the OCEANIC-STROKE Randomized, Placebo-Controlled Trial: FXIa Inhibition by Asundexian in Participants With Noncardioembolic Stroke or Transient Ischemic Attack by Nonlaboratory Framingham Risk Score Category (OCEANIC-STROKE)*
· A Randomized Controlled Trial of Spironolactone-Based Blood Pressure Management After Stroke (REDUCE)
· Intensive Blood-Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Prior Stroke: The OPTIMAL-Stroke Trial
LBS.03: Hot Topics in CVD Prevention
3:15-4:30 p.m. | Saturday, Nov. 7
· Discontinuing Statins in Multimorbid Older Adults Without Cardiovascular Disease: A Randomized Noninferiority Clinical Trial (STREAM)
· Intensive Blood Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Type 2 Diabetes — The OPTIMAL-DIABETES Trial
· Statin-Ezetimibe Combination Therapy vs. Statin Monotherapy in Patients With Atherosclerotic Cardiovascular Disease: Prespecified Second Randomization of the Ez-PAVE Trial (Ez-PAVE)*
· Yoga-Based Cardiac Rehabilitation in Heart Failure With Reduced Ejection Fraction (Yoga-CaRe HF Trial)
LBS.04: Innovations to Optimize Arrhythmia Care
3:30-4:45 p.m. | Sunday, Nov. 8
· Left Bundle Branch Pacing vs. Right Ventricular Pacing for Atrioventricular Block: An International Multicenter Randomized Controlled Trial (OptimPacing Study)
· Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation: COAST-AF Randomized Trial
· Sacubitril/Valsartan for Preventing Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Hypertension: A Multicenter, Randomized Controlled Trial (SUPERIOR)
· Randomized Cluster Evaluation of Cardiac ARrest Systems (RACE-CARS) Trial Primary Results (RACE-CARS)*
LBS.05: New Frontiers in Cardiometabolic Risk Reduction
8-9:15 a.m. | Monday, Nov. 9
· TYDAL-TIMI 78: A Randomized Trial of ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol Concentrations (TYDAL-TIMI 78)
· CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b Trial (CXT310)
· Orforglipron for the Treatment of Obstructive Sleep Apnea: Results From Attain-OSA (ATTAIN-OSA)
· Survodutide and Cardiovascular Outcomes in Obesity: Results From the SYNCHRONIZE®-CVOT Trial
LBS.06: Artificial Intelligence in the Diagnosis of Cardiovascular Disease
9:45-11 a.m. | Monday, Nov. 9
· Consumer Smartwatch Artificial Intelligence-Enabled Electrocardiogram for Left Ventricular Systolic Dysfunction: Cross-Manufacturer Validation and Serial Home Monitoring (WATCH-LV)
· AI-Enabled Tele-ECG Identifies Structural Heart Disease and Prioritizes Echocardiography in Underserved Populations: The PROVAR+ External Validation Study
· AI-Assisted Comprehensive Echocardiographic Interpretation — A Blinded, Randomized Controlled Trial
· All-Cause and Cardiovascular Mortality in the U.S.: Risk Stratification via Integrated AI-Enabled Coronary Plaque Analysis and FFRCt in Over 269,000 Patients
